Loading...
Loading...
LRMR| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 49.0K |
| Gross Profit | -49.0K |
| Operating Expense | 9,620.0K |
| Operating I/L | -9,620.0K |
| Other Income/Expense | 1,254.0K |
| Interest Income | 0.0K |
| Pretax | -8,366.0K |
| Income Tax Expense | -46.1K |
| Net Income/Loss | -8,366.0K |
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing treatments for rare diseases. The company's primary focus is on leveraging its innovative cell penetrating peptide technology platform to create therapeutic solutions. Its lead product candidate, CTI-1601, is currently undergoing Phase 1 clinical trials for the treatment of Friedreich's ataxia, a rare and fatal genetic disease. Larimar Therapeutics aims to generate revenue through the development and commercialization of novel therapies targeting rare diseases, addressing unmet medical needs and improving the lives of patients.
